Abstract
Skin and skin adnexa toxicities are the most common side effects associated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Previous research showed that the rash appeared, and the severity of EGFR-TKIs may be a marker of clinical benefit. In this context, we report a 75-year-old man with advanced lung cancer who on receiving icotinib developed severe adverse reactions, 4 degree rash (NCI-CTC AE version 4.0 common toxicity grading standards grade), and refused to stop taking the drug; but with the anti-infection and symptomatic nursing, the patient recovered, the rash disappeared, and the patient received a better prognosis. Thus, we would like to emphasize the importance of deciding whether to stop the drug when patients developed adverse reactions of 3-4 degree rash.
Highlights
Icotinib is a first-generation EGFR-TKI developed by Zhejiang Beta Pharma in China, which is the first small molecular targeted drugs and has gained international recognition [1]
We report a 75-year-old man with advanced lung cancer who received icotinib, developed severe adverse reactions, and refused to stop taking the drug, but through anti-infection the rash disappeared and the patient received a better prognosis
EGFR-TKIs inhibitor development has shown great superiority in the treatment of lung cancer, but it brings a variety of skin toxicity [7]
Summary
Icotinib is a first-generation EGFR-TKI developed by Zhejiang Beta Pharma in China, which is the first small molecular targeted drugs and. We report a 75-year-old man with advanced lung cancer who received icotinib, developed severe adverse reactions, and refused to stop taking the drug, but through anti-infection the rash disappeared and the patient received a better prognosis. The chest computed tomography (CT) scan showed: left lower lobe mass shadow, more likely to consider the surrounding lung cancer, bilateral middle volume of pleural effusion; bone scan showed multiple metastatic bone lesions. Through the combination of tumor markers detection and clinical manifestations, he was considered to be diagnosed with lung adenocarcinoma and clinically staged as cT2aN0M1b, stage IV This patient was given “bevacizumab 100mg and cisplatin 30mg and normal saline 20ml” pleural perfusion chemotherapy 2 times. CEA: Carcinoembryonic Antigen; CA: Carbohydrate Antigen; NSE: Neuron Specific Enolase; -: without detection;
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call